Clearmind Medicine Receives Positive DSMB Recommendation for CMND-100 Clinical Trial

Key Facts

1The independent Data and Safety Monitoring Board (DSMB) issued a positive recommendation to continue the Phase I/IIa clinical trial of CMND-100.

2The CMND-100 drug candidate is being developed for the treatment of Alcohol Use Disorder (AUD).

Clearmind Medicine Inc. (Nasdaq: CMND) has announced a positive recommendation from the independent Data and Safety Monitoring Board (DSMB) to proceed with its Phase I/IIa clinical trial. The trial focuses on CMND-100, a drug candidate specifically developed for the treatment of Alcohol Use Disorder (AUD). Following a thorough review of safety data, the DSMB found no concerns that would necessitate modifications or the termination of the ongoing study. This recommendation marks a significant safety milestone for the biotech firm, effectively reducing the clinical risk profile of the CMND-100 program. The company remains on track with its clinical development timeline as it seeks to address the global health challenge of alcohol addiction. Investors view this as a necessary step toward proving the long-term viability and safety of the treatment.